CIK 0001453687 · Non-accelerated filer<br>Smaller reporting company
Cartesian Therapeutics, Inc.
Sign in to watch- Ticker
- RNAC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 301-348-8698
- Business address
- 7495 NEW HORIZON WAY, FREDERICK, MD, 21703
- Former names
- SELECTA BIOSCIENCES INC
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Director bought 30,000 shares at $6.86 ($205,797)
- 4 Option exercise Chief Operations Officer acquired 7,500 shares (option exercise)
- 4 Gift Director gave 20,000 shares (gift)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Option exercise Chief Operations Officer acquired 7,500 shares (option exercise)
- 4 Option exercise Chief Operations Officer acquired 7,500 shares (option exercise)
- 4 Open-market buy Director bought 149,075 shares at an average $10.21 ($1,522,517)
- 4 Open-market buy Director bought 89,863 shares at an average $15.26 ($1,371,154)
- 4 Open-market buy Director bought 20,967 shares at an average $17.47 ($366,354)
- 4 Option exercise Chief Scientific Officer acquired 9,000 shares (option exercise)
- 4 Open-market sale Chief Technology Officer sold 4,875 shares at an average $16.78 ($81,790)
- 4 Open-market sale Chief Medical Officer sold 1,880 shares at an average $16.78 ($31,542)
- 4 Open-market sale Chief Scientific Officer sold 2,550 shares at an average $16.78 ($42,783)
- 4 Open-market sale Chief Operations Officer sold 1,797 shares at an average $16.78 ($30,149)
- 4 Open-market sale President and CEO sold 17,271 shares at an average $16.78 ($289,764)
- 4 Open-market sale Chief Financial Officer sold 7,989 shares at an average $16.78 ($134,036)
- 4 Grant or award President and CEO acquired 57,500 shares (grant or award)
- 4 Grant or award Chief Scientific Officer acquired 16,100 shares (grant or award)
Page 2 of 21 · 410 filings